| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:329.)
© 2008 American Heart Association, Inc.
Original Contributions |
From The Russell H. Morgan Department of Radiology and Radiological Sciences (B.A.W., D.A.B.) and the Department of Pathology (S.L.), The Johns Hopkins University School of Medicine, Baltimore, Md; the Department of Epidemiology (A.R.S.), The Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; the Department of Radiological Sciences (A.S.G.), University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, Calif; the Departments of Medicine and Pathology (M.C.), University of Vermont, Burlington, Vt; the Division of Epidemiology (A.R.F.), School of Public Health, University of Minnesota, Minneapolis, Minn; the Division of Prevention and Population Sciences (D.E.B.), National Heart, Lung, and Blood Institute, Bethesda, Md; the Department of Biostatistics (R.A.K.), School of Public Health and Community Medicine, University of Washington, Seattle, Wash; and the Department of Radiology (S.S.), University of California at San Diego Medical Center, San Diego, Calif.
Correspondence to Bruce A. Wasserman, MD, The Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins Hospital, Phipps B-100, 600 N. Wolfe Street, Baltimore, MD 21287. E-mail bwasser{at}jhmi.edu
| Abstract |
|---|
|
|
|---|
Methods— The Multi-Ethnic Study of Atherosclerosis (MESA) is a multicenter cohort study of individuals free of clinical cardiovascular disease designed to include a high proportion of ethnic minorities. We selected MESA participants from the top 15th percentile of maximum carotid intima media thickness by ultrasound and acquired high-resolution black blood MRI images through their carotid plaque before and after the intravenous administration of gadodiamide (0.1 mmol/kg). Lumen and outer wall contours were defined using semiautomated analysis software. We analyzed only plaques with a maximum thickness
1.5 mm by MRI (n=214) and assessed cross-sectional risk factor associations with lipid core presence by multivariable logistic regression.
Results— A lipid core was present in 151 (71%) of the plaques. After controlling for age, ethnicity, sex, maximum arterial wall thickness, hypertension, cigarette smoking, diabetes, and C-reactive protein, compared with participants in the lowest tertile of total plasma cholesterol, the ORs of having a lipid core for participants in the middle and highest tertiles were 2.76 (95% CI: 1.01 to 7.51) and 4.63 (95% CI: 1.56 to 13.75), respectively. None of the other risk factors was associated with lipid core.
Conclusions— In persons with thickened carotid walls, plasma total cholesterol, but not other established coronary heart disease risk factors, is strongly associated with lipid core presence by MRI. High total cholesterol may be associated with rupture proneness of atherosclerotic lesions in the general population.
Key Words: atherosclerosis carotid artery cholesterol lipid core magnetic resonance MRI risk factors stroke
| Introduction |
|---|
|
|
|---|
Cerebral events can be precipitated by plaque rupture resulting from fibrous cap foam-cell infiltration and cap thinning, similar to the mechanism of coronary plaque rupture leading to myocardial events.4 Clinical implications of carotid plaque morphology extend beyond the risk of stroke for that lesion. Carotid atherosclerosis reflects generalized atherosclerosis.5,6 Moreover, the composition of a carotid plaque might reveal the vulnerability of atherosclerotic disease elsewhere.7,8
MRI can noninvasively characterize human carotid atheroma composition.9–12 It detects a variety of lipid mixtures commonly found in human atherosclerotic plaque, allowing for its delineation in vivo.11 MRI has enabled demonstration of a marked reduction in lipid content in carotid atheroma during administration of lipid-lowering therapy.13 After the administration of a gadolinium-based contrast agent, the fibrous tissue shows preferential uptake, which allows for greater conspicuity of the lipid core.12,14–16
Using this technique, we explored the associations of cardiovascular risk factors with lipid-rich plaque in a free-living population without a history of cardiovascular disease events.
| Methods |
|---|
|
|
|---|
Study Groups
In each of the 6 MESA centers, 100 participants with carotid atherosclerosis were randomly selected from the top 15th percentile of maximum intima media thickness of either the right or left internal carotid artery measured by B-mode ultrasound at the baseline MESA examination 2 years prior. Participants with contraindications to MRI were excluded. A total of 577 participants was studied.
MRI Examinations
MRI examinations were performed on a 1.5-T MRI scanner (3 sites used CV/i scanners; GE Medical Systems; one site used a Quantum version Mobile scanner or an Avanto platform and 2 sites used a Sonata platform; Siemens Medical Systems). Bilateral carotid receive-only coils were fixed over each side of the neck. A bilateral 4-channel phased-array coil (Machnet) was used with the Siemens scanners and dual 3-inch surface coils (GE Medical Systems) were used with the GE scanners.
A 3-dimensional time-of-flight MR angiogram was acquired to localize the carotid bifurcations. Three proton-density-weighted black blood images were oriented through the long axis of the bifurcation on the side selected based on thickness. These images were used to position 5 T1- and T2-weighted fat-suppressed black blood images perpendicular to the area of greatest wall thickness with the middle slice traversing the most stenotic point (Figure 1). Black blood images were acquired using a double inversion recovery fast spin echo sequence using peripheral pulse gating. Parameters are shown in Table 1. The acquired resolution was 2 mmx0.54 mmx0.54 mm.
|
|
Participants who agreed to the administration of gadolinium received an intravenous injection of 0.1 mmol/kg gadodiamide (Omniscan; GE Healthcare) at a rate of 2 mL/s through a power injector. The 5 T1-weighted transverse black blood images were repeated 5 minutes after gadolinium administration.
MRI Analysis
The postcontrast transverse image showing the largest lipid core area (Figure 2), or the thickest wall if no core was present, was analyzed using Vesselmass software (VesselMass, Division of Image Processing, Radiology Department, Leiden University Medical Center). Window and level settings were set to constant levels to standardize signal intensities for each analyzed image. Two analysts drew lumen, lipid core, and outer wall contours on this image using the software. Contours were reviewed by an experienced MRI physician. All observers were blinded to characteristics of the study population. The postcontrast image was used based on reports that gadolinium enhancement improves delineation of the lipid core and outer wall.12,16,18 The corresponding T2-weighted image was used to confirm lipid core delineation when questionable on the postcontrast series, and the corresponding precontrast T1-weighted image was used to confirm the lumen contour when flow artifact from gadolinium was present.
|
The vessel wall was divided into 12 radial segments by a semiautomated feature of Vesselmass software (Figure 3). Arteries with a maximum segmental wall thickness less than 1.5 mm were excluded because of the resolution limitation of this technique. No lipid cores were excluded by this criterion.
|
Risk Factor Measurements
Blood was drawn after an overnight fast for inflammatory marker measurements (a high-sensitivity assay for C reactive protein [CRP] and interleukin 6 [IL-6]) at the baseline clinic visit (18 to 26 months before the MRI) and then again within 30 days of the MRI examination for plasma total and high-density lipoprotein (HDL) cholesterol and plasma triglyceride measurements. All blood samples were sent to a central laboratory. Plasma total and HDL cholesterol was measured using a cholesterol oxidase method and triglyceride using the Triglyceride GB reagent on a Roche COBAS FARA centrifugal analyzer (Roche Diagnostics). Analytical coefficients of variation were 1.6%, 2.9%, and 4.0%, respectively. Low-density lipoprotein (LDL) cholesterol concentration was calculated using the Friedewald formula.19 We restricted our analysis of LDL to participants with plasma triglyceride
400 mg/dL because LDL is not estimated accurately for those with higher values using this equation. CRP and IL-6 were measured in batches. CRP was measured by particle-enhanced immunonephelometry using the BNII nephelometer (N High Sensitivity CRP; Dade Behring Inc) with interassay analytical coefficients of variation ranging from 2.1% to 5.7%. IL-6 was measured by ultrasensitive enzyme-linked immunosorbent assay (Quantikine HS Human IL-6 Immunoassay; R&D Systems) with an analytical coefficient of variation of 6.3%.
Resting blood pressure was measured 3 times in the right arm after 5 minutes in the seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon). The average of the last 2 measurements was used for analysis. Hypertension was defined as either an average systolic blood pressure of 140 mm Hg or above, an average diastolic blood pressure of 90 mm Hg or above, or taking antihypertensive medication.
Body mass index was determined using the following formula: weight(kg)/height(m)2. Cigarette smoking status was categorized as never, former, or current. Ever was defined as
100 cigarettes in ones lifetime; current was defined as smoking cigarettes within the past 30 days.
Impaired fasting glucose and diabetes mellitus were defined by 1997 American Diabetes Association fasting criteria as a fasting glucose of 110 to 125 mg/dL and of
126 mg/dL, respectively. Use of insulin or oral diabetes medication was also considered diagnostic for diabetes.
Statistical Analysis
Intraobserver and interobserver variability of lipid core detection by MRI were estimated by rereading 10% of cases 3 months after the initial reading. SAS software (version 9.1) was used for all analyses. Multivariable logistic regression was used to predict lipid core presence from the following variables: age, sex, ethnicity, and coronary risk factors (cholesterol, smoking, diabetes and impaired fasting glucose, hypertension, CRP or IL-6, and carotid wall thickness by MRI). Inclusion of the wall thickness variable in the model assures that the results for other variables pertain to their relationship to core presence, not just their size.
| Results |
|---|
|
|
|---|
Interobserver agreement for the presence of a lipid core was present for 19 of 22 cases studied (86%, kappa: 0.70). Intraobserver agreement was present for 19 of 21 cases (90%, kappa: 0.81). Age, ethnicity, and distributions of key variables are shown in Table 2 together with the prevalence of a lipid core based on risk factor levels.
|
The independent associations of demographic and risk factors with lipid core presence are shown in Table 3. Compared with participants in the lowest tertile of total cholesterol, adjusted ORs of having a lipid core for participants in the middle and highest tertiles were 2.76 (95% CI: 1.01 to 7.51) and 4.63 (95% CI: 1.56 to 13.75), respectively. The presence of a lipid core was associated significantly with carotid wall thickness but not with any other cardiovascular risk factor (ie, hypertension, smoking, diabetes, CRP concentration). The cholesterol associations were not substantially altered by further adjustment for use of lipid lowering medication (Table 3). When IL-6 tertiles replaced CRP in the model, IL-6 was not significantly associated with lipid core presence, but the association between lipid core presence and cholesterol remained strong (data not shown). We also considered total cholesterol divided into quintiles and found a stepwise increase with the strongest association in the highest quintile (>226 mg/dL) compared with the lowest quintile with an OR of 6.35 (95% CI: 1.60 to 25.2). Cholesterol associations remained significant after adjusting for use of lipid-lowering medications with only slight changes in ORs.
|
Although none of the standard risk factors appeared to be associated with lipid core presence, we in fact were adequately powered to detect effect sizes of moderate strength or greater. For example, we had 80% power to detect ORs of 1.38 or greater for smoking, 1.31 or greater for diabetes or impaired fasting glucose, 1.31 or greater for hypertension, and 1.29 or greater for upper tertile of CRP.
In a model in which total cholesterol was replaced by LDL cholesterol and HDL cholesterol, ORs for the second and third tertiles of LDL cholesterol were 2.22 (0.84 to 5.87) and 3.08 (1.01 to 9.34), respectively, and for HDL cholesterol were 1.26 (0.44 to 3.64) and 1.45 (0.44 to 4.77), respectively. In a similar model with non-HDL cholesterol and HDL cholesterol, ORs for non-HDL cholesterol tertiles, 3.41 (1.26 to 9.21) and 3.92 (1.31 to 11.7), respectively, were stronger than for LDL cholesterol tertiles as shown in the previously mentioned model. HDL cholesterol associations remained nonsignificant. Triglyceride levels were not independently associated with lipid core presence.
| Discussion |
|---|
|
|
|---|
We studied a large diverse population of asymptomatic individuals. Compared with small studies of patients whose plaques have ruptured and caused symptoms, use of an asymptomatic population has the advantage of reduced potential for selection bias and greater assurance that the risk factor associations observed relate to the causes of lipid-rich plaques rather than reflecting the effects of medical intervention or other lifestyle modifications consequent to manifest carotid disease.
Burke et al20 reported that lipids and white race but not smoking or hypertension were associated with the presence of a thin fibrous cap overlying a lipid-rich core in coronary atheromas of autopsied men with coronary disease who died suddenly. Our findings, on a sample of both men and women, substantially extend those of Burke from fatal disease to the types of lipid-filled plaques found in living populations and reduce the likelihood that they are the result of the potential biases seen with populations selected for autopsy.
It might be argued that risk factors established for coronary plaque features are less applicable to carotid disease. However, atherosclerosis is a systemic process and there is evidence that the composition and clinical consequences of plaques at different locations within an individual are similar.8 Honda et al21 showed that carotid plaque echolucency, which suggests lipid or intraplaque hemorrhage,22 in stable patients with coronary artery disease predicted future coronary events independent of other risk factors. Hence, our cholesterol associations have implications beyond stroke risk assessment.
Ultrasound studies of the echolucency of carotid plaques have generally shown associations with plasma lipids.23–25 Although these associations are implicitly related to core lipid content, ultrasound is unable to discriminate lipid from intraplaque hemorrhage, which might be a destabilizing factor that could influence the associations with clinical outcomes.26
Surprisingly, we found that lipid cores tended to be much less prevalent in carotid walls of blacks than whites. Although the finding was not statistically significant, it is consistent with the findings of Burke et al,20 who reported substantially and significantly fewer lipid-rich vulnerable plaques in black compared with white men with coronary disease who died suddenly.
The lack of an association in our study between CRP and core presence is noteworthy because CRP has been strongly associated with plaque rupture27,28 and predicts stroke risk.29 Along with our findings, this suggests that CRP may be a marker of plaque instability independent of presence of a lipid core.
It should be noted that the thin cap/large core atheroma is not the only lesion at risk for thrombosis. The "erosive plaque," lacking an endothelium, exposes the underlying intima with consequent thrombosis.30 A core, if present, is usually small. If plaques prone to erosion are not associated with elevated cholesterol, as suggested,31 they could account for the lower cholesterol levels in our noncore group.
Study limitations include: (1) the acquired in-plane resolution of the MRI images was 0.54 mmx0.54 mm. We excluded individuals with wall thicknesses <1.5 mm because no cores were apparent in thinner walls and small cores could be missed; (2) the sample sizes were too small to identify race–ethnic-specific risk factor associations; (3) we studied only one carotid artery per participant, targeting the thickest wall, but this does not fully characterize his or her lipid core burden. Because we expect this error to be nondifferential with respect to risk factors, the association we observed between lipid core and plasma cholesterol is likely to be underestimated; and (4) rheological factors may have some influence on the development of a lipid core. This was not assessed in this study due to the complexity of geometrically characterizing atheromatous plaque location.
Summary
This study of the MESA population offers unique insight into a population not subject to the selection and cause–effect biases encountered with symptomatic cohorts. Plasma cholesterol was clearly the most important determinant of the putatively thrombogenic lipid core, which portends risk for rupture. It is increasingly recognized that clinically silent, vulnerable plaques can carry a significant risk for rupture, but risk stratification is both difficult and important given the high prevalence of these lesions. We found a lipid core in 71% of the thickest carotid walls selected from this asymptomatic population. Smaller vulnerable plaques, not detectable by MRI, would add to overall population prevalence. If the evaluation of patients with carotid plaques included scanning for a lipid core, this knowledge might provide the basis for more aggressive cholesterol-reducing therapy.
| Acknowledgments |
|---|
Sources of Funding
This research was supported by contracts R01-HL-69905, N01-HC-95159 through N01-HC-95166, and N01-HC-95168 from the National Heart, Lung, and Blood Institute. GE Healthcare supplied the MRI contrast agent.
Disclosures
None.
Received July 9, 2007; accepted July 18, 2007.
| References |
|---|
|
|
|---|
2. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994; 89: 36–44.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657–671.
4. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg. 1996; 23: 755–765;discussion 765–756.
5. Bots ML, Hofman A, Grobbee DE. Common carotid intima-media thickness and lower extremity arterial atherosclerosis. The Rotterdam Study. Arterioscler Thromb. 1994; 14: 1885–1891.
6. OLeary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340: 14–22.
7. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003; 108: 1664–1672.
8. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, Biedermann BC. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation. 2004; 110: 2843–2850.
9. Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol. 1999; 19: 2756–2761.
10. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996; 94: 932–938.
11. Yuan C, Petty C, OBrien KD, Hatsukami TS, Eary JF, Brown BG. In vitro and in situ magnetic resonance imaging signal features of atherosclerotic plaque-associated lipids. Arterioscler Thromb Vasc Biol. 1997; 17: 1496–1503.
12. Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, Takaya N, Polissar NL, Yuan C. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation. 2005; 112: 3437–3444.
13. Zhao XQ, Yuan C, Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR, Brown BG. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case–control study. Arterioscler Thromb Vasc Biol. 2001; 21: 1623– 1629.
14. Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, Hatsukami TS. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002; 15: 62–67.[CrossRef][Medline] [Order article via Infotrieve]
15. Wasserman BA, Casal SG, Astor BC, Aletras AH, Arai AE. Wash-in kinetics for gadolinium-enhanced magnetic resonance imaging of carotid atheroma. J Magn Reson Imaging. 2005; 21: 91–95.[CrossRef][Medline] [Order article via Infotrieve]
16. Wasserman BA, Smith WI, Trout HH 3rd, Cannon RO 3rd, Balaban RS, Arai AE. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. Radiology. 2002; 223: 566–573.
17. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR, Kronmal R, Liu K, Nelson JC, OLeary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156: 871–881.
18. Zhang S, Cai J, Luo Y, Han C, Polissar NL, Hatsukami TS, Yuan C. Measurement of carotid wall volume and maximum area with contrast-enhanced 3D MR imaging: initial observations. Radiology. 2003; 228: 200–205.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499–502.[Abstract]
20. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336: 1276–1282.
21. Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S, Kojima S, Hirai N, Kawano H, Soejima H, Sakamoto T, Yoshimura M, Ogawa H. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol. 2004; 43: 1177–1184.
22. Polak JF, Shemanski L, OLeary DH, Lefkowitz D, Price TR, Savage PJ, Brant WE, Reid C. Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. Cardiovascular Health Study. Radiology. 1998; 208: 649–654.
23. Gronholdt ML, Nordestgaard BG, Wiebe BM, Wilhjelm JE, Sillesen H. Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation. 1998; 97: 34–40.
24. Kofoed SC, Gronholdt ML, Bismuth J, Wilhjelm JE, Sillesen H, Nordestgaard BG. Echolucent, rupture-prone carotid plaques associated with elevated triglyceride-rich lipoproteins, particularly in women. J Vasc Surg. 2002; 36: 783–792.[Medline] [Order article via Infotrieve]
25. Mathiesen EB, Bonaa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the Tromso study. Stroke. 2001; 32: 1960–1965.
26. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, Isaac C, McDonough J, Natiello C, Small R, Ferguson MS, Hatsukami TS. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation. 2005; 111: 2768–2775.
27. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002; 105: 2019–2023.
28. Sano T, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, Fukuda D, Shimada K, Yoshikawa J. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003; 108: 282–285.
29. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003; 108: 166–170.
30. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262–1275.
31. Virmani R, Burke AP, Farb A. Plaque rupture and plaque erosion. Thromb Haemost. 1999; 82 (suppl 1): 1–3.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
C. Miao, S. Chen, R. Macedo, S. Lai, K. Liu, D. Li, B. A. Wasserman, J. Vogel-Clausen, J. A.C. Lima, and D. A. Bluemke Positive remodeling of the coronary arteries detected by magnetic resonance imaging in an asymptomatic population: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1708 - 1715. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J CHURCH Imaging Diabetes Radiol. Technol., March 1, 2009; 80(4): 340 - 360. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |